Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner.


BACKGROUND AIMS Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic cell transplantation (HCT). Recent literature demonstrates a potential benefit of human mesenchymal stromal cells (MSC) for the treatment of refractory GvHD; however, the optimal dose remains uncertain. We set out to develop an animal model that can… (More)
DOI: 10.3109/14653240903502712

6 Figures and Tables


  • Presentations referencing similar topics